Unbound MEDLINE

Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index. HIV medicine [HIV Med] Journal article

 
TitleDiagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index.
Author(s)Resino S, Micheloud D, Miralles P, Bellón JM, Vargas A, Catalán P, Alvarez E, Cosín J, Lorente R, López JC, Muñoz-Fernández MA, Berenguer J 
InstitutionLaboratory of Molecular Epidemiology of Infectious Diseases, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
SourceHIV Med 2009 Aug 3.
AbstractBackground Noninvasive tests are increasingly being used for the assessment of liver fibrosis. We aimed to develop a serum index for the identification of advanced fibrosis (F>/=3) in HIV/hepatitis C virus (HCV)-coinfected patients. Methods We carried out a cross-sectional study on a group of 195 patients comprised of an estimation group (EG; n=127) and a validation group (VG; n=68) who all underwent liver biopsy and had not received previous interferon therapy. Liver fibrosis was estimated using the METAVIR score. We developed a new serum index (HGM-3) dependent on levels of platelets, alkaline phosphatase, hepatic growth factor, tissue inhibitor of metalloproteinase-1 and hyaluronic acid. Results In the EG, the area under the receiver operating characteristic curve (AUC-ROC) of HGM-3 for identification of F>/=3 was 0.939 [95% confidence interval (CI) 0.899, 0.979] which was significantly higher than the AUC-ROC of the HGM-2, FIB-4, aspartate aminotransferase to platelet ratio (APRI) and Forns' indexes. With HGM-3 <0.135 for F<3, 57 patients were correctly identified and two patients were misclassified. We found the presence of F<3 with 96.6% certainty. The negative likelihood ratio (LR) was <0.1 and the diagnostic odds ratio (DOR) was >40. With HGM-3 >0.570 in the EG for F>/=3, 31 patients were correctly identified, and five patients were misclassified. We found the presence of F>/=3 with 86.1% certainty. The positive LR was >12 and the DOR was >40. For the VG, the diagnostic accuracy values were similar to the values for the EG. Conclusions HGM-3 appears to be an accurate noninvasive method for the diagnosis of bridging fibrosis and cirrhosis in HIV/HCV-coinfected patients.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19686437
  
Advertise on this site.